Back

The quest continues: Human CD4+ CD16+ CD56+ "exTreg" resemble NKT cells instead

Mutha, J.; Konga, M.; Sprang, M.; Mayer, J. U.; Schlenner, S. M.

2025-08-07 immunology
10.1101/2025.08.05.667656 bioRxiv
Show abstract

Regulatory T cells are essential for immune tolerance, but their loss of function under inflammatory conditions in murine models signify a risk factor for Treg-based therapies. Recently CD4+ CD56+ CD16+ T cells were suggested to resemble such ex-Treg in human PBMC. Here, we re-evaluate the identity of the CD4+ CD56+ CD16+ population at a phenotypic and transcriptomic level using multiparametric flow cytometry on human PBMC and CITE-seq analysis to demonstrate that the CD4+ CD56+ CD16+ cells mostly constitute NKT cells instead. Further, we evaluated the stability of human Treg under lineage-challenging conditions and observe robust lineage stability in vitro. Finally, we also explore the potential of Tr17 induction using TGF-{beta} and IL-6, a possible therapeutic strategy for Treg ex vivo expansion-based therapies. Together, we conclude that human exTreg remain to be described and instead human Treg present as remarkably stable, further promoting Treg-based adoptive transfer therapies.

Matching journals

The top 6 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.